Mid-stage data reported at the ESMO congress in Barcelona showed that ponsegromab was able to increase weight by 5.6% at the most effective dose, above the 5% threshold deemed clinically meaningful, and Pfizer is now thinking about starting a phase 3 programme for the drug next year.

Ponsegromab reached a clinically meaningful 5.6% mean weight increase at the high dose level in patients with cancer cachexia.

Pharma giant Pfizer said that a drug aimed at helping cancer patients losing appetite and muscle mass showed positive results in a Phase 2 trial.

Pfizer Inc.'s experimental drug for cancer weight loss was shown to help patients regain weight in a mid-stage study, offering fresh promise for treating the dangerous muscle-wasting condition. In cancer patients,

Pfizer Inc.'s experimental drug for cancer weight loss was shown to help patients regain weight in a mid-stage study, offering fresh promise for treating the dangerous muscle-wasting condition.

Cancer patients with wasting syndrome have gained weight after taking Pfizer’s anti-GDF-15 antibody in a midphase study, emboldening the Big Pharma to target a 2025 start date for its pivotal trial program.

Pfizer Inc.’s experimental drug for cancer weight loss was shown to help patients regain weight in a mid-stage study, offering fresh promise for treating the dangerous muscle-wasting condition. In

Pfizer's (PFE) experimental therapy for cancer related weight loss, ponsegromab, meets the primary endpoint in Phase 2 trial. Read more here.